Tirzepatide statistics 2026: Mounjaro and Zepbound prescriptions, sales, trial results and pricing

Medicare Part D enrollees took Mounjaro in 2024, up from 54,000 in 2022¹

Mounjaro claims were filled in Medicare Part D in 2024, up from 122,000 in 2022¹

of 2024 Medicare Part D gross spending on GLP-1 drugs went to Mounjaro¹

Total gross Part D GLP-1 spending was $27.5 billion in 2024.

shares of 88.2 million US GLP-1 prescriptions dispensed from January 2023 to September 2024 that were for Mounjaro and Zepbound²

Covers Ozempic, Mounjaro, Wegovy and Zepbound only. IQVIA National Prescription Audit data.

of Zepbound prescriptions were written for female patients, compared with 63% of Mounjaro prescriptions²

January 2023 to September 2024.

of young adults ages 18 to 25 dispensed a GLP-1 in 2023 had tirzepatide as their most recent GLP-1³

IQVIA prescription data.

Mounjaro worldwide revenue in 2025, up 99% from $11,540 million in 2024⁴

US Mounjaro revenue was $13,651 million and outside the US $9,315 million.

Zepbound worldwide revenue in 2025, up 175% from $4,926 million in 2024⁴

Almost all of it was in the US ($13,484 million).

of Eli Lilly's total 2025 revenue came from Mounjaro and Zepbound⁴

Mounjaro worldwide revenue in the second quarter of 2026, up 91%⁵

US revenue was $4.8 billion (up 45%) and revenue outside the US was $5.2 billion (up 172%).

Zepbound worldwide revenue in the second quarter of 2026, up 46%⁵

US Zepbound revenue rose 44% to $4.9 billion, partly offset by lower realized prices including cash-pay price cuts.

Mounjaro revenue in the first half of 2026, up 106%; Zepbound revenue was $9,088 million, up 60%⁵

decline in Lilly's US realized prices in 2025, which the company says was driven mainly by Mounjaro and Zepbound⁴

average weight loss at 72 weeks with tirzepatide 15 mg in SURMOUNT-1, vs 3.1% with placebo⁶

2,539 adults with obesity, or overweight with a weight-related complication, without diabetes. The 5 mg and 10 mg doses produced 15.0% and 19.5%.

of SURMOUNT-1 participants on 15 mg lost 20% or more of body weight, vs 3% on placebo⁶

50% of the 10 mg group reached that threshold. At least 5% loss was reached by 91% on 15 mg vs 35% on placebo.

of SURMOUNT-1 participants on 15 mg stopped treatment because of adverse events, vs 2.6% on placebo⁶

Rates were 4.3% for 5 mg and 7.1% for 10 mg.

average weight loss at 72 weeks with tirzepatide vs semaglutide in the head-to-head SURMOUNT-5 trial⁷

751 adults with obesity without type 2 diabetes, each on their maximum tolerated dose. Waist circumference fell 18.4 cm vs 13.0 cm.

average weight regained by SURMOUNT-4 participants switched to placebo after 36 weeks of tirzepatide, vs a further 5.5% loss among those who stayed on it⁸

Week 36 to week 88. Participants had lost 20.9% in the lead-in; overall loss from week 0 to 88 was 25.3% on tirzepatide vs 9.9% on placebo.

events per hour change in the apnea-hypopnea index at 52 weeks on tirzepatide in the two SURMOUNT-OSA trials, vs placebo⁹

Placebo groups changed by -5.3 and -5.5 events per hour. Baseline AHI was 51.5 and 49.5 events per hour.

HbA1c reduction with tirzepatide 15 mg at 40 weeks in SURPASS-2, vs -1.86 points with semaglutide 1 mg¹⁰

1,879 adults with type 2 diabetes. All three tirzepatide doses were noninferior and superior to semaglutide.

additional weight loss with tirzepatide 15 mg compared with semaglutide 1 mg in SURPASS-2¹⁰

Differences were 1.9 kg for 5 mg and 3.6 kg for 10 mg.

of SURPASS-CVOT patients had a primary cardiovascular event on tirzepatide vs dulaglutide¹¹

13,299 patients with type 2 diabetes and atherosclerotic cardiovascular disease were randomized; the primary event was cardiovascular death, heart attack or stroke. Hazard ratio 0.92, meeting noninferiority but not superiority.

of SUMMIT patients with heart failure with preserved ejection fraction and obesity had cardiovascular death or worsening heart failure on tirzepatide vs placebo¹²

731 patients; hazard ratio 0.62; median follow-up 104 weeks.

per month list price of Zepbound cited by the White House before its November 2025 pricing agreement with Eli Lilly¹³

monthly self-pay price for the Zepbound 2.5 mg vial through LillyDirect; 5 mg is $399 and 7.5 mg to 15 mg are $449¹⁴

Lower prices for higher doses require refilling within 45 days. Needles and syringes are bought separately.

average monthly Zepbound price on TrumpRx.gov, as low as $299 depending on dose¹⁵

The February 2026 fact sheet lists a pre-deal price of $1,088.

monthly copay for eligible Medicare beneficiaries using Zepbound KwikPen for weight management under the Medicare GLP-1 Bridge from July 1, 2026¹⁶

Single-dose Zepbound vials and pens are not covered under the Bridge.

monthly price Medicare pays for Mounjaro and Zepbound under the November 2025 agreement¹³

The same price applies to Ozempic and Wegovy.

monthly self-pay price for the lowest dose of Foundayo (orforglipron), Lilly's oral GLP-1 for weight loss approved April 1, 2026¹⁷

Foundayo is not tirzepatide; it is included here as Lilly's lower-cost alternative. Foundayo revenue was $98 million in Q2 2026.

year tirzepatide injection went into shortage due to increased demand¹⁸

date of the FDA decision that the tirzepatide injection shortage is resolved¹⁸

FDA first announced the resolution on October 2, 2024, then reissued the decision.

end of FDA enforcement discretion for outsourcing facilities (503B) compounding tirzepatide¹⁸

The period for state-licensed pharmacies (503A) originally ran until February 18, 2025 and ended after a March 5, 2025 court ruling.

adverse event reports linked to compounded tirzepatide had been received by the FDA as of May 31, 2026¹⁹